Does Dr. Prillaman study ovarian cancer?

Yes, Dr. Prillaman focuses on ovarian cancer, particularly the platinum-resistant type.

What treatments has Dr. Prillaman researched?

She has researched the combination of relacorilant and nab-paclitaxel to improve survival rates in patients.

Is Dr. Prillaman's work relevant to patients with platinum-resistant ovarian cancer?

Yes, her research is directly aimed at improving treatment options and outcomes for patients with this specific condition.

CHRISTINA W. PRILLAMAN, MD FACP

WILLIAMSBURG, VA

Research Active

Internal Medicine - Hematology & Oncology NPI registered 21+ years 1 publication 2026 – 2026 NPI: 1316942964

Internal Medicine - Hematology & Oncology

Ovarian NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsDrug Resistance, NeoplasmPyrazolesPyridinesProgression-Free SurvivalReceptors, GlucocorticoidPaclitaxelAlbuminsIsoquinolines

Practice Location

500 SENTARA CIRCLE
WILLIAMSBURG, VA 23188-5727

Phone: (757) 229-2236

What does CHRISTINA PRILLAMAN research?

Dr. Prillaman studies ovarian cancer, particularly a difficult-to-treat type known as platinum-resistant ovarian cancer. This condition occurs when cancer does not respond to traditional platinum-based chemotherapy. She investigates new treatment options like relacorilant in combination with nab-paclitaxel, a type of chemotherapy, to see if this combination can provide better outcomes for patients. Her research aims to improve survival rates and overall health for those battling this challenging form of cancer.

Key findings

Patients receiving the combination of relacorilant and nab-paclitaxel experienced a 46% overall survival rate at 18 months, compared to 27% for those on nab-paclitaxel alone.
The average overall survival increased by 4.1 months with the combination therapy, providing patients with an average of 16 months of survival as opposed to 11.9 months with standard treatment.
This study suggests the combination may serve as a new standard treatment for patients with platinum-resistant ovarian cancer.

Frequently asked questions

Does Dr. Prillaman study ovarian cancer?: Yes, Dr. Prillaman focuses on ovarian cancer, particularly the platinum-resistant type.
What treatments has Dr. Prillaman researched?: She has researched the combination of relacorilant and nab-paclitaxel to improve survival rates in patients.
Is Dr. Prillaman's work relevant to patients with platinum-resistant ovarian cancer?: Yes, her research is directly aimed at improving treatment options and outcomes for patients with this specific condition.

Publications in plain English

Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.

2026

Lancet (London, England)

Lorusso D, Gladieff L, O'Malley DM, Kim JW, Garbaos G +36 more

Plain English
This study looked at the effects of adding a drug called relacorilant to the chemotherapy nab-paclitaxel in patients with platinum-resistant ovarian cancer. Researchers found that patients who received both treatments had a 46% overall survival rate at 18 months, compared to just 27% for those who received nab-paclitaxel alone, with an average overall survival increase of 4.1 months (16 months vs. 11.9 months). These results are important because they show that the combination treatment could become a new standard option for patients struggling with this form of cancer. Who this helps: Patients with platinum-resistant ovarian cancer.

PubMed

Frequent Co-Authors

Domenica Lorusso Laurence Gladieff David M O'Malley Jae-Weon Kim Gabriel Garbaos Anna Fagotti Lucy Gilbert Linda Mileshkin Stanislas Quesada Elizabeth Hopp

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.